Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a …

J Trigo, R Hitt, P Koralewski, E Diaz-Rubio… - Journal of Clinical …, 2004 - ascopubs.org
5502 Background: Pts with refractory SCCHN have a poor prognosis with few therapeutic
options. Cetuximab (Erbitux), an IgG1 monoclonal antibody that binds selectively to EGFR …
被引用次数：194 相关文章

[引用][C] Cetuximab monotherapy is active in patients with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). Results of …

J TRIGO - J Clin Oncol, 2004 - cir.nii.ac.jp
Cetuximab monotherapy is active in patients with platinum-refractory recurrent/metastatic
squamous cell carcinoma of the head and neck (SCCHN). Results of phase II study | CiNii …